oxazolidin-2-one has been researched along with Hyperlipemia in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adam, S; Durrington, PN; Soran, H | 1 |
| Bell, TA; Crooke, RM; Fu, W; Graham, MJ; Lee, RG; Mullick, AE; Norris, D | 1 |
| Corr, C; De Lepeleire, I; Garg, A; Handa, N; Jin, B; Krishna, R; Maes, A; Shah, J; Van Dyck, K; Wadhwa, T; Wagner, JA | 1 |
| Bloomfield, D; Dansky, HM; Gibbons, P; Littlejohn, TW; Liu, S; McKenney, JM; Mitchel, Y; Sisk, CM; Tribble, D | 1 |
| Burnett, JR; Hooper, AJ | 1 |
| Ghosh, RK; Ghosh, SM | 1 |
| Goswami, D; Gurule, S; Khuroo, A; Monif, T; Saha, A; Vats, P | 1 |
2 review(s) available for oxazolidin-2-one and Hyperlipemia
| Article | Year |
|---|---|
Optimising treatment of hyperlipidaemia: Quantitative evaluation of UK, USA and European guidelines taking account of both LDL cholesterol levels and cardiovascular disease risk.
Topics: Anticholesteremic Agents; Atorvastatin; Cardiology; Cardiovascular Diseases; Cholesterol, LDL; Europe; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Oxazolidinones; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Risk Factors; United Kingdom; United States | 2018 |
Current status of CETP inhibitors in the treatment of hyperlipidemia: an update.
Topics: Amides; Animals; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Esters; Humans; Hyperlipidemias; Oxazolidinones; Quinolines; Risk Factors; Sulfhydryl Compounds | 2012 |
2 trial(s) available for oxazolidin-2-one and Hyperlipemia
| Article | Year |
|---|---|
Effect of diltiazem, a moderate CYP3A inhibitor, on the pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein inhibitor, in healthy subjects.
Topics: Adolescent; Adult; Cholesterol Ester Transfer Proteins; Cytochrome P-450 CYP3A Inhibitors; Delayed-Action Preparations; Diltiazem; Drug Interactions; Enzyme Inhibitors; Female; Half-Life; Humans; Hyperlipidemias; Linear Models; Male; Middle Aged; Oxazolidinones; Young Adult | 2011 |
Efficacy and safety after cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib (MK-0859) in patients with primary hypercholesterolemia or mixed hyperlipidemia.
Topics: Cholesterol Ester Transfer Proteins; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Hyperlipidemias; Male; Middle Aged; Oxazolidinones; Withholding Treatment | 2011 |
3 other study(ies) available for oxazolidin-2-one and Hyperlipemia
| Article | Year |
|---|---|
Antisense oligonucleotide inhibition of cholesteryl ester transfer protein enhances RCT in hyperlipidemic, CETP transgenic, LDLr-/- mice.
Topics: Animals; Anticholesteremic Agents; Aorta; Biological Transport; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Combined Modality Therapy; Gene Expression; Gene Knockdown Techniques; Hyperlipidemias; Lipoproteins, LDL; Liver; Macrophages; Male; Mice; Mice, Knockout; Oligonucleotides, Antisense; Oxazolidinones; Receptors, LDL; RNA Interference; Triglycerides | 2013 |
Anacetrapib, a cholesteryl ester transfer protein inhibitor.
Topics: Animals; Atherosclerosis; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Oxazolidinones | 2012 |
Metaxalone estimation in biological matrix using high-throughput LC-MS/MS bioanalytical method.
Topics: Adult; Chromatography, Liquid; Drug Stability; Hemolysis; High-Throughput Screening Assays; Humans; Hyperlipidemias; Linear Models; Male; Oxazolidinones; Reproducibility of Results; Sensitivity and Specificity; Solid Phase Extraction; Tandem Mass Spectrometry | 2012 |